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The introduction of all-trans retinoic acid (ATRA) and arsenic trioxide has brought about tremendous advancement in the
treatment of acute promyelocytic myelogenous leukemia (APML). In most instances, the beneﬁts of these treatments outweigh the
risks associated with their respective safety proﬁles. Although acute pancreatitis is not commonly associated with arsenic toxicity,
it should be considered as a possible side eﬀect. We report a case of arsenic-induced pancreatitis in a patient with APML.
1.Introduction
Acute promyelocytic myelogenous leukemia (APML), ﬁrst
reported in 1957, accounts for approximately 10%–15% of
cases of acute myeloid leukemia in adults [1–3]. Before the
1980s, this disease was among the most fatal at presentation
or during induction; however, the introduction of all-trans
retinoic acid (ATRA) and arsenic trioxide has brought about
tremendous advancement in treatment strategies, with the
majority of newly diagnosed and relapsed patients being able
to be cured with these agents [4, 5]. Arsenic trioxide induces
remission in 70%–85% of adults with newly diagnosed or
refractory acute promyelocytic leukemia [6]. In general, the
beneﬁts of both therapies in patients with APML outweigh
the risks associated with their respective safety proﬁles.
However, we report a case of arsenic-induced pancreatitis in
a patient with APML.
2.CaseReport
A 24-year-old female with a past medical history of chole-
cystectomy and APML presented to the hospital with a
2-day history of nausea, vomiting, and epigastric pain.
Her oncologic history included induction chemotherapy
with cytarabine, daunorubicin, and ATRA 1 year prior
to presentation. One year after induction therapy, she
had clinical relapse, and therapy was changed to arsenic
trioxide at a dose of 0.15mg/kg/day (17mg daily), which
was administered intravenously 5 days per week for an
anticipated 20 dose total. On Day 11 of therapy, the
patient developed the current symptoms of nausea, vom-
iting, and epigastric pain. Physical examination revealed
tenderness in the epigastrium. With regard to laboratory
data, the patient had an elevated amylase level (405U/L;
normal 30–110U/L), an elevated aspartate aminotransferase
level (43U/L; normal 14–36U/L), an elevated lipase level
(4960U/L; normal 6–75U/L), and a low hemoglobin level
(9.8g/dL; normal 12.3–15.3g/dL). Computed tomography
(CT) scan of the abdomen/pelvis showed evidence of prior
cholecystectomy. Right upper quadrant ultrasound revealed
a normal pancreas, a common bile duct 3.5mm without
intrahepatic ductal dilation, a surgically absent gallbladder,
and a normal liver. Magnetic resonance imaging (MRI)
and magnetic resonance cholangiopancreatography (MRCP)
revealed normal pancreatic morphology with no evidence of
pancreas divisum. Bile aspirate was negative for microcrys-
talline disease. Triglycerides, antinuclear antibodies (ANA),
and IgG4 levels were negative. Arsenic therapy was held
during the hospitalization. The patient responded well
to intravenous ﬂuids, pain control, and antiemetics. Her
biochemical parameters normalized by hospital day 8.
One week later, arsenic therapy was reintroduced at
a dose of 0.1mg/kg/day. On day 14 of therapy, the pa-
tient developed mental status changes, respiratory distress,
hypotension, and recurrent pancreatitis with elevated amy-
lase and lipase levels. CT of the abdomen and pelvis revealed
heterogeneity of the pancreas consistent with pancreatitis.
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a chelating agent for suspected arsenic toxicity. Blood and
urine toxicology levels of arsenic were signiﬁcantly elevated
25 days after cessation of therapy. Further workup for the
altered mental status included EEGs which revealed general-
ized slowing consistent with toxic metabolic encephalopathy.
The patient eventually required a tracheostomy and a per-
cutaneous gastrojejunostomy and was transferred to a skilled
long-term care facility.
3. Discussion
Arsenic is a naturally occurring element that is found in the
earth’s crust. It has a long been used in various commercial
and industrial products, pharmaceuticals, and as an agent of
deliberate poisoning [7]. Arsenic poisoning has been known
to occur through industrial exposure from contaminated
wine or moonshine but also through contamination of
herbal preparations and nutritional supplements in addition
to conditions involving attempted suicide. Arsenic is com-
monly also found in its organic and inorganic form in many
foods such as dairy products, beef, poultry, rice, pork, and
cereal.
Although arsenic has long been known to act as a car-
cinogen in the human skin, lung, liver, kidney, and urinary
bladder,arsenictrioxide(As2O3)hasalsobeendemonstrated
to have anticancer activity in acute promyelocytic leukemia
[8]. Several mechanisms of action may contribute to the
anticancer activity of arsenic trioxide. Studies have found
that in acute promyelocytic leukemia cellsand cell lines,
low arsenic trioxide concentrations (0.1 to 0.5μM) resulted
in degradation of PML-RARα proteins, relocation of PML
into nuclear bodies, and partial diﬀerentiation. Higher
concentrations (0.5 to 2μM) induced apoptosis through the
formationofreactiveoxygenspecies(ROS),includinghydro-
gen peroxide and superoxide, which resulted in oxidative
stress, DNA damage, and the activation of Jun N-terminal
kinase (JNK), triggering apoptosis [9–16]. It appears that
there may be a role for direct islet cell injury of the pancreas,
particularly endocrine cellular components of pancreatic
islets. In addition, when examination of oral exposure of
arsenic trioxide was performed in rabbits, elevated serum
amylase activity and enhanced activity of oxidative stress
have been found [17]. The presence of nitrite accumulation,
lipid peroxidation, and resultant development of diabetes
fromchronicoralexposureofarsenichasalsobeendescribed
[17].
Arsenic has been suggested to be involved in cytotoxicity
and genotoxicity by generation of nitric oxide and lipid
peroxide [17]. Arsenic toxicity can result in a number of
symptoms and side eﬀects including cardiovascular, neur-
ologic, dermatologic, hematologic, and hepatotoxic manifes-
tations. Gastrointestinal side eﬀects from arsenic poisoning
are common and well described. Symptoms of acute arsenic
toxicity include nausea, vomiting, and colicky abdominal
pain.Profusewaterydiarrheaisoftenseen.Inchronicarsenic
toxicity, neurological side eﬀects and skin manifestations are
especially common.
The early clinical course of arsenic intoxication often
mimics gastroenteritis. Symptoms can develop from 30
minutes to several hours following ingestion [18]. Values
greater than 50–100ug/24 hours are suggestive of arsenic
intoxication [18]. A fatal dose ranges between 100mg and
300mg, although smaller doses may also be life-threatening
[18, 19].
Arsenic-induced pancreatitis, whether secondary to in-
tentional, accidental, or as part of chemotherapeutic therapy,
is rare. An extensive review of the literature revealed 3
cases of arsenic-induced pancreatitis. In 1985, a case report
describes a healthy 38-year-old female who presented with
nausea, vomiting, and diarrhea 2 hours after ingesting
herbal tea [18]. In this case, analysis of the patient’s unused
herbal tea bags as well as a variety of household items
including kitchen powders, fertilizers, and garden supplies
for arsenic were negative. Examination of family members
revealed normal blood studies and no detectable arsenic by
Gutzeit test in the urine. The patient was evaluated by a
psychiatrist who noted the patient to be a reliable historian
andwithouthomicidalorsuicidaltendencies[18].Urinalysis
forheavymetalsshowedanarseniclevelof9000μg/24hours.
The herbal tea was ultimately implicated as the source of
arsenic. In 2006, there was a second case report of a 77-
year-old male who suﬀered from acute pancreatitis during
treatment of relapsed acute promyelocytic leukemia with
arsenic trioxide after 25 days of therapy [20]. The third case
involved a 26-year-old male with a history of surreptitious
oraladministrationofaprobable10gofarsenictrioxidewho
developed pancreatitis and toxic hepatitis. Despite chelation
therapy with dimercaprol and dimercaptosuccinic acid, the
patient died of multiple organ failure [21].
Acute pancreatitis is not commonly associated with
arsenic toxicity especially when used for chemotherapeutic
purposes. Although seemingly rare, it should be considered
as a possible side eﬀect and should certainly be part of
the diﬀerential diagnosis of drug-induced pancreatitis. It
is unclear if dose reduction of arsenic trioxide aids in
the prevention of subsequent episodes of pancreatitis. It
is also unclear if therapy with arsenic trioxide should be
discontinued after the ﬁrst episode of pancreatitis provided
all other etiologies are excluded. Further studies are needed
to evaluate and analyze this clinical issue.
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